Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome

Major depressive disorder (MDD) is accompanied with an imbalance in the immune system and cardiovascular impairments, such as atherosclerosis. Several mechanisms have been pointed out to underlie this rather unexpected association, and among them the activity of myeloperoxidase (MPO). The aim of our study was to find compounds that inhibit both MPO and serotonin transporter (SERT) for treating MDD associated with cardiovascular diseases.

[1]  B. Cravatt,et al.  Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling. , 2013, Biochemistry.

[2]  E. Gouaux,et al.  Structural basis for action by diverse antidepressants on biogenic amine transporters , 2013, Nature.

[3]  Eric Gouaux,et al.  X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.

[4]  C. Obinger,et al.  Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. , 2013, Journal of medicinal chemistry.

[5]  L. Vanhamme,et al.  Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. , 2012, Talanta.

[6]  M. J. Núñez,et al.  Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. , 2011, Basic & clinical pharmacology & toxicology.

[7]  A. Kettle,et al.  2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation* , 2011, The Journal of Biological Chemistry.

[8]  M. Saridi,et al.  Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[9]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[10]  H. Mayberg,et al.  Stuck in a rut: rethinking depression and its treatment , 2011, Trends in Neurosciences.

[11]  H. Lane,et al.  A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. , 2010, Thrombosis research.

[12]  Rodolfo do Couto Maia and Carlos Alberto Manssour Fraga.  Discovery of Dual Chemotherapy Drug Candidates Designed by Molecular Hybridization , 2010 .

[13]  C. Obinger,et al.  Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. , 2010, Journal of medicinal chemistry.

[14]  B. Beno,et al.  Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. , 2010, Journal of medicinal chemistry.

[15]  M. Maes,et al.  Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. , 2010, Journal of affective disorders.

[16]  W. Siess,et al.  Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood , 2010, Thrombosis and Haemostasis.

[17]  B. Jin,et al.  Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson’s Disease , 2010, The Journal of Immunology.

[18]  S. Nicholls,et al.  Biomarkers of inflammation and oxidative stress in atherosclerosis. , 2010, Biomarkers in medicine.

[19]  Sang Ki Park,et al.  Depression research: where are we now? , 2010, Molecular Brain.

[20]  Masafumi Ueno,et al.  Basic principles of platelet biology and clinical implications. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[21]  K. Boudjeltia,et al.  A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. , 2009, Talanta.

[22]  I. López-Vílchez,et al.  Serotonergic mechanisms enhance platelet-mediated thrombogenicity , 2009, Thrombosis and Haemostasis.

[23]  Anil Kumar,et al.  Protective effects of antidepressants against chronic fatigue syndrome – induced behavioral changes and biochemical alterations , 2009, Fundamental & clinical pharmacology.

[24]  J. Richards.  Patent issues relating to hybrid drugs , 2008 .

[25]  V. Vaccarino,et al.  Association of Major Depressive Disorder with Serum Myeloperoxidase and Other Markers of Inflammation: A Twin Study , 2008, Biological Psychiatry.

[26]  B. Meunier,et al.  Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.

[27]  L. Çelik,et al.  Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. , 2008, Journal of the American Chemical Society.

[28]  C. Obinger,et al.  Myeloperoxidase: a target for new drug development? , 2007, British journal of pharmacology.

[29]  Jimin Pei,et al.  PROMALS: towards accurate multiple sequence alignments of distantly related proteins , 2007, Bioinform..

[30]  M. Nazıroğlu,et al.  Protective Effects of Lamotrigine, Aripiprazole and Escitalopram on Depression-induced Oxidative Stress in Rat Brain , 2007, Neurochemical Research.

[31]  D. Atar,et al.  Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study , 2007, Neuropsychopharmacology.

[32]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[33]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[34]  B. Beno,et al.  Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. , 2005, Journal of medicinal chemistry.

[35]  S. Hazen,et al.  Myeloperoxidase and cardiovascular disease. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  S. Klebanoff.  Myeloperoxidase: friend and foe , 2005, Journal of leukocyte biology.

[37]  C. Obinger,et al.  Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. , 2005, Biochemical pharmacology.

[38]  J. Macor,et al.  Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). , 2005, Bioorganic & medicinal chemistry letters.

[39]  B. Elfving,et al.  The Chicken Serotonin Transporter Discriminates between Serotonin-selective Reuptake Inhibitors , 2004, Journal of Biological Chemistry.

[40]  O. Wiborg,et al.  Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants , 2004, The European journal of neuroscience.

[41]  S. Khanzode,et al.  Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors , 2003, Redox report : communications in free radical research.

[42]  D. Atar,et al.  Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin , 2003, European journal of heart failure.

[43]  R. de la Torre,et al.  Synthesis of the major metabolites of paroxetine. , 2003, Bioorganic chemistry.

[44]  W. Pearson,et al.  Current Protocols in Bioinformatics , 2002 .

[45]  R. Blakely,et al.  Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. , 2001, Molecular pharmacology.

[46]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[47]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[48]  H. Neels,et al.  Immune Disturbances in Treatment‐Resistant Depression: Modulation by Antidepressive Treatments , 1997 .

[49]  E. Bosmans,et al.  Indicators of immune activation in major depression , 1996, Psychiatry Research.

[50]  B. Vogt,et al.  Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione , 1989, Brain Research.

[51]  S. Håkansson,et al.  Comparative acute toxicity of paroxetine and other antidepressants , 1989, Acta psychiatrica Scandinavica. Supplementum.

[52]  J. Metcalf,et al.  Myeloperoxidase deficiency: prevalence and clinical significance. , 1981, Annals of internal medicine.

[53]  A. Kettle,et al.  Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. , 2009, The Biochemical journal.

[54]  K. Ley,et al.  Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.

[55]  W. Daniel,et al.  Platelets and Blood Cells , 2004 .

[56]  W. J. Steen.  Assessing overmedication: Biology, philosophy and common sense , 2003 .

[57]  W. J. van der Steen.  Assessing Overmedication: Biology, Philosophy and Common Sense , 2003, Acta biotheoretica.

[58]  J. Kelly,et al.  The toxicity profile of a single dose of paroxetine: an alternative approach to acute toxicity testing in the rat. , 2001, Pharmacology & toxicology.